Advisory Board

Meet our team of leaders, researchers, and advisors.

Chief Medical Officer  

Dr. Marco Pappagallo, MD

Dr. Marco Pappagallo, MD completed his medical school and a post-graduate training in neurosurgery at the University of Rome, Italy. He completed his residency training in Neurology at the State University of New York at Stony Brook. In 1990 he obtained a position as clinical and research fellow in pain medicine at Johns Hopkins University, Baltimore, MD. After his pain fellowship, he became faculty member of the Departments of Neurology, Neurosurgery and Anesthesiology and Medical Director of Chronic Pain at Hopkins. In 1999 Dr. Pappagallo moved to the Hospital of Joint Diseases – New York University, NY as Director of the Comprehensive Pain Center. In 2003 he joined the Department of Pain and Palliative Care at Beth Israel Medical Center in New York City, NY as Director of Chronic Pain. From 2006 till 2011 he worked at the Mount Sinai Medical Center, NYC, NY where he held the position of Professor and Director of Pain Research in the Department of Anesthesiology. In 2010 Dr. Pappagallo co-founded the start-up NovaPharm Therapeutics (NPT - Wayne, PA) where he operated as Chief Medical Officer. NPT001 asset was subsequently acquired by Grünenthal. Dr. Marco Pappagallo began to work with Grünenthal (GRT)-US as Medical Expert-in-Residence and Executive Director of Medical Intelligence. He collaborated with the GRT-US regulatory team in compiling the initial application concerning the Breakthrough Therapy Designation (BTD) for neridronate in CRPS, which was eventually granted by the FDA in Dec 2016. Since 2011, he has directed the New Medical Home for Chronic Pain in NYC, NY. In July 2014 Dr. Pappagallo was named Clinical Professor of Anesthesiology at the Albert Einstein College of Medicine, Bronx, NY and in January 2015 he became Co-director of the Pain Management Center at Overlook Medical Center in Summit, NJ.


Dr. Ted Price, PhD

Theodore (Ted) Price returned to the School of Behavioral and Brain Sciences at UTD as an Associate Professor in 2014. He graduated from UTD in 1998 with a B.S. in Neuroscience where he worked with Dr. Alice O'Toole on human face perception. He then received his PhD in 2003 from the University of Texas Health Science Center at San Antonio under the mentorship of Christopher Flores and Kenneth Hargreaves. He was then a postdoctoral fellow in the laboratory of Fernando Cervero at McGill University until 2007. Dr. Price was a faculty member of The University of Arizona School of Medicine from 2007-2014 with funding from the National Institutes of Health (NIH), Rita Allen Foundation, and Migraine Research Foundation. Dr. Price is the recipient of Young Investigator Awards from the American Pain Society and International Association for the Study of Pain, has published more than 70 peer-reviewed articles in international journals, serves as the pharmacology section editor for European Journal of Pain and is on the editorial board for Pain, Molecular Pain and The European Journal of Neuroscience. He is also a regular reviewer for National Institutes of Health and American Pain Society study sections.


Dr. Greg Dussor, PhD

Gregory (Greg) Dussor received his PhD in Pharmacology at The University of Texas Health Science Center in San Antonio in 2002 under the mentorship of Drs. Chris Flores and Ken Hargreaves after receiving his BS in biochemistry at the University of Alabama. Following his PhD studies, he did postdoctoral training from 2004-2007 in the laboratory of Dr. Ed McCleskey at the Vollum Institute on the campus of The Oregon Health & Science University in Portland. In 2007, he joined the Faculty in the Department of Pharmacology at the University of Arizona in Tucson. While in Arizona, he shifted the focus of his laboratory to understanding the pathophysiology contributing to chronic headache disorders such as migraine. He remained on faculty there until joining the School of Behavioral and Brain Sciences in 2014. Greg was a recipient of a Future Leaders in Pain Research Award from the American Pain Society, he has received funding from the NIH, the American Pain Society, the National Headache Foundation, and the Migraine Research Foundation, he is on the Editorial Board for the journal PAIN, and he regularly serves as a study section member at NIH/CSR.


Dr. David U’Prichard, PhD

Dr. David C. U’Prichard is the former CSO, and current Advisory Board Chair and member of the Board of Managers of BioMotiv LLC (Cleveland). He also serves as a President of Druid Consulting LLC, consulting to the pharmaceutical and biotechnology industries from his base in Philadelphia, US, and as a Partner at Druid BioVentures LLP (Philadelphia). Dr. U’Prichard is a director of Arix Bioscience plc (LSE: ARIX), a public global healthcare and life science company focused on generating value from the development and commercialisation of innovative technologies, based in London and New York. From 2005 until 2009, he was a Venture Partner at Red Abbey Venture Partners (Baltimore). During 2003 – 2006, he was a Venture Partner for Apax Partners Ltd. (London) and Care Capital LLC (Princeton). From 1999 to 2003 he was CEO of 3-Dimensional Pharmaceuticals, Inc., Yardley PA. During that time he took 3DP public and secured large collaborations with Bristol-Myers Squibb and Johnson & Johnson. In March 2003, 3DP become a part of Johnson & Johnson Pharmaceutical R&D. From 1997 to 1999, Dr. U'Prichard served as Chairman of Research and Development at SmithKline Beecham, managing 8000 R&D staff, and a portfolio of 200 projects. Prior to SmithKline Beecham, he worked for ICI/Zeneca from 1986 to 1997, as Executive Vice President and International Research Director from 1994 to 1997. While at Zeneca and SmithKline Beecham, Dr. U’Prichard oversaw the discovery and development of a number of successful drugs including Seroquel®, Accolate®, Avandia® and Iressa®. Previously, Dr. U'Prichard as CSO was instrumental in the launch of Nova Pharmaceuticals, Baltimore MD in 1983, following an academic career as tenured Associate Professor of Pharmacology and Neurobiology at Northwestern University Medical School (1978-83), and his postdoctoral fellowship at The Johns Hopkins University (1975-78). Dr. U'Prichard received his Ph.D. in Pharmacology from the University of Kansas, and his B.S. in Pharmacology with first-class honors from the University of Glasgow, Scotland. He has held academic appointments at Northwestern University, The Johns Hopkins University and the University of Pennsylvania and is an Honorary Professor at the University of Glasgow. He is also an author of more than 100 primary and review publications, was a founding co-editor of Molecular Neurobiology, co-editor of Epinephrine in the Central Nervous System and has served as a member of various editorial boards. Dr. U'Prichard chairs the boards of Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC, Berkeley Heights, NJ), Vala Sciences Inc. (La Jolla, CA), and additionally Dual Therapeutics Inc. (Cleveland) and Orca Pharmaceuticals Ltd. (Oxford), two of BioMotiv’s investment companies. He also serves on the board of directors of Iroko Pharmaceuticals LLC and Churchill Pharmaceuticals (Philadelphia), and Splash Pharmaceuticals (La Jolla, CA). Dr. U’Prichard was Chairman of the Pennsylvania Biotechnology Association 2004-2005, and has served on the boards of BIO, BioAdvance (the Biotechnology Greenhouse of Southeastern Pennsylvania), Ben Franklin Technology Partners of Southeastern Pennsylvania, and the Bioethics Institute of the University of Pennsylvania. Dr. U’Prichard was Chair of the Executive Board of Stratified Medicine Scotland, a national academic-industry consortium supported by the Government of Scotland. Dr. U’Prichard was a consultant for Booz & Co., and is a board member of the International House of Philadelphia, and ex-Chairman of the Board of Trustees, The Wilma Theater, also in Philadelphia.


Dr. Nigel Calcutt, PhD

Dr. Calcutt took his B.Sc. in Zoology and Ph.D. Physiology and Pharmacology at Nottingham University, England. Following post-doctoral research at St. Bartholomew’s Hospital, London and at the University of California San Diego, he was appointed to the faculty of the Department of Pathology at UCSD in 1993. Dr. Calcutt first began studying nerve damage caused by diabetes as an undergraduate, with a largely unsuccessful, but nevertheless entertaining, attempt to generate diabetic chickens. Undeterred by the paucity of pre-diabetic poultry, he has continued to investigate mechanisms of diabetic neuropathy and neuropathic pain throughout his career, with a particular interest in developing therapies than can be translated to clinical use. Dr. Calcutt’s research is funded by the National Institutes of Health and the American Diabetes Association. He is a co-founder of WinSanTor Inc. and the non-profit organization Diabetes Research Connection.


Dr. Neil Singla, MD

Dr. Neil Singla, a board-certified anesthesiologist, is the founder and Chief Executive Officer of Lotus Clinical Research. Since its inception in 2001, Dr. Singla has served in several roles within the organization including: Research Coordinator, Sub-Investigator, Principal Investigator, Coordinating Investigator, and Chief Scientific Officer.

In his capacity as CEO for Lotus Clinical Research, Dr. Singla has had the opportunity to interact frequently with the FDA’s Analgesics Division on behalf of clients and to play a significant role in guiding development strategies for dozens of putative analgesic agents. In the company’s 17-year history, Dr. Singla and Lotus Clinical Research have played a significant role in bringing several molecules to market.

Dr. Singla has published extensively and is a frequent lecturer for physicians, pharmaceutical companies, and medical research institutes throughout the country. He currently chairs the Analgesic Clinical Trials Shared/Special Interest Group at both the American Pain Society (APS) and the International Association for the Study of Pain (IASP). He chairs the annual APS Conference on Analgesic Clinical Trials (APS-CAT), which aims to help experts advance best practices in analgesic drug development.

The main focus of Dr. Singla’s academic endeavors has been to analyze and understand how the inherent variability in subjective endpoint analgesic clinical trials can be minimized. As a result, he has developed novel techniques for patient education designed to minimize variability, reduce placebo response, and increase effect size.